nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0396	0.0419	CbGpPWpGaD
Alfuzosin—ADRA1D—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0338	0.0358	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0329	0.0348	CbGpPWpGaD
Alfuzosin—ADRA1D—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0328	0.0347	CbGpPWpGaD
Alfuzosin—ADRA1D—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0306	0.0323	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0292	0.0309	CbGpPWpGaD
Alfuzosin—ADRA1D—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0284	0.0301	CbGpPWpGaD
Alfuzosin—ADRA1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0281	0.0297	CbGpPWpGaD
Alfuzosin—ADRA1D—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0276	0.0292	CbGpPWpGaD
Alfuzosin—ADRA1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0272	0.0288	CbGpPWpGaD
Alfuzosin—ADRA1D—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0257	0.0272	CbGpPWpGaD
Alfuzosin—ADRA1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0254	0.0268	CbGpPWpGaD
Alfuzosin—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0249	0.0264	CbGpPWpGaD
Alfuzosin—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0242	0.0256	CbGpPWpGaD
Alfuzosin—ADRA1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0236	0.0249	CbGpPWpGaD
Alfuzosin—ADRA1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0229	0.0242	CbGpPWpGaD
Alfuzosin—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0225	0.0238	CbGpPWpGaD
Alfuzosin—ADRA1D—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0214	0.0227	CbGpPWpGaD
Alfuzosin—ADRA1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0213	0.0226	CbGpPWpGaD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.021	0.0222	CbGpPWpGaD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0203	0.0215	CbGpPWpGaD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.019	0.02	CbGpPWpGaD
Alfuzosin—ADRA1D—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.018	0.019	CbGpPWpGaD
Alfuzosin—ADRA1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0178	0.0188	CbGpPWpGaD
Alfuzosin—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0158	0.0167	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.015	0.0159	CbGpPWpGaD
Alfuzosin—ADRA1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0149	0.0158	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0146	0.0154	CbGpPWpGaD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0133	0.014	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00951	0.0101	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00859	0.00908	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00784	0.00829	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00653	0.0069	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00633	0.0067	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0059	0.00624	CbGpPWpGaD
Alfuzosin—ADRA1B—nervous system—Gilles de la Tourette syndrome	0.00559	0.103	CbGeAlD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00559	0.00591	CbGpPWpGaD
Alfuzosin—ADRA1D—nervous system—Gilles de la Tourette syndrome	0.00547	0.101	CbGeAlD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00543	0.00574	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00542	0.00573	CbGpPWpGaD
Alfuzosin—ADRA1B—central nervous system—Gilles de la Tourette syndrome	0.00538	0.099	CbGeAlD
Alfuzosin—ADRA1D—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00535	0.00565	CbGpPWpGaD
Alfuzosin—ADRA1D—central nervous system—Gilles de la Tourette syndrome	0.00527	0.0968	CbGeAlD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00526	0.00556	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00506	0.00535	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0049	0.00518	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00481	0.00509	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00478	0.00506	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00467	0.00494	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00464	0.00491	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0045	0.00476	CbGpPWpGaD
Alfuzosin—ADRA1B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00444	0.00469	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00435	0.0046	CbGpPWpGaD
Alfuzosin—ADRA1B—brain—Gilles de la Tourette syndrome	0.00428	0.0786	CbGeAlD
Alfuzosin—ADRA1D—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00426	0.0045	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.0042	0.00444	CbGpPWpGaD
Alfuzosin—ADRA1D—brain—Gilles de la Tourette syndrome	0.00418	0.0768	CbGeAlD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00413	0.00437	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00413	0.00437	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00412	0.00436	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.004	0.00423	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00397	0.0042	CbGpPWpGaD
Alfuzosin—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00394	0.00417	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00385	0.00407	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00373	0.00394	CbGpPWpGaD
Alfuzosin—KCNH2—midbrain—Gilles de la Tourette syndrome	0.00369	0.0678	CbGeAlD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00354	0.00374	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00353	0.00374	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00353	0.00373	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00343	0.00363	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00343	0.00363	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0032	0.00338	CbGpPWpGaD
Alfuzosin—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.00314	0.0577	CbGeAlD
Alfuzosin—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00314	0.00332	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00305	0.00322	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00305	0.00322	CbGpPWpGaD
Alfuzosin—KCNH2—nervous system—Gilles de la Tourette syndrome	0.00303	0.0558	CbGeAlD
Alfuzosin—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.00303	0.0556	CbGeAlD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00294	0.00311	CbGpPWpGaD
Alfuzosin—KCNH2—central nervous system—Gilles de la Tourette syndrome	0.00292	0.0537	CbGeAlD
Alfuzosin—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00284	0.003	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0027	0.00285	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00261	0.00276	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00241	0.00254	CbGpPWpGaD
Alfuzosin—ADRA1A—brain—Gilles de la Tourette syndrome	0.0024	0.0441	CbGeAlD
Alfuzosin—ADRA1D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00234	0.00247	CbGpPWpGaD
Alfuzosin—KCNH2—brain—Gilles de la Tourette syndrome	0.00232	0.0426	CbGeAlD
Alfuzosin—ADRA1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00224	0.00237	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00218	0.00231	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00218	0.0023	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00212	0.00224	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.002	0.00211	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00199	0.0021	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00198	0.00209	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00194	0.00205	CbGpPWpGaD
Alfuzosin—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00188	0.0346	CbGeAlD
Alfuzosin—ADRA1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00181	0.00192	CbGpPWpGaD
Alfuzosin—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00181	0.0333	CbGeAlD
Alfuzosin—ADRA1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00181	0.00191	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00177	0.00188	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00176	0.00186	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00172	0.00182	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00164	0.00173	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00161	0.0017	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.0016	0.0017	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00156	0.00165	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00152	0.00161	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00146	0.00154	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00138	0.00146	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00129	0.00136	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00126	0.00134	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00125	0.00133	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.00119	0.00126	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00117	0.00123	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00115	0.00121	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00112	0.00119	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00107	0.00113	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00104	0.0011	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00102	0.00108	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000969	0.00102	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000952	0.00101	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000924	0.000977	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000861	0.00091	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000817	0.000865	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000679	0.000718	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000603	0.000637	CbGpPWpGaD
